Gallacher Capital Management LLC Makes New Investment in Edwards Lifesciences Co. (NYSE:EW)

Gallacher Capital Management LLC bought a new stake in shares of Edwards Lifesciences Co. (NYSE:EW) in the 4th quarter, Holdings Channel.com reports. The institutional investor bought 3,003 shares of the medical research company’s stock, valued at approximately $222,000.

A number of other institutional investors and hedge funds have also made changes to their positions in EW. FSA Wealth Management LLC bought a new stake in shares of Edwards Lifesciences during the third quarter valued at approximately $30,000. Migdal Insurance & Financial Holdings Ltd. acquired a new stake in Edwards Lifesciences in the 4th quarter valued at approximately $30,000. Prospera Private Wealth LLC bought a new stake in Edwards Lifesciences during the 3rd quarter valued at $32,000. Avior Wealth Management LLC boosted its position in Edwards Lifesciences by 138.7% during the 3rd quarter. Avior Wealth Management LLC now owns 530 shares of the medical research company’s stock worth $35,000 after acquiring an additional 308 shares during the period. Finally, Roble Belko & Company Inc acquired a new position in Edwards Lifesciences during the 4th quarter worth $46,000. 79.46% of the stock is currently owned by institutional investors and hedge funds.

Edwards Lifesciences Trading Up 2.1 %

Shares of NYSE EW opened at $69.37 on Monday. The firm has a market capitalization of $40.78 billion, a PE ratio of 9.95, a PEG ratio of 4.82 and a beta of 1.12. Edwards Lifesciences Co. has a one year low of $58.93 and a one year high of $96.12. The company has a current ratio of 3.46, a quick ratio of 2.89 and a debt-to-equity ratio of 0.06. The business has a 50-day moving average price of $71.74 and a two-hundred day moving average price of $70.34.

Edwards Lifesciences (NYSE:EW) last announced its quarterly earnings data on Tuesday, February 11th. The medical research company reported $0.59 EPS for the quarter, beating analysts’ consensus estimates of $0.55 by $0.04. Edwards Lifesciences had a net margin of 72.93% and a return on equity of 19.40%. As a group, analysts predict that Edwards Lifesciences Co. will post 2.45 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of brokerages recently weighed in on EW. Evercore ISI reduced their price objective on shares of Edwards Lifesciences from $75.00 to $73.00 and set an “in-line” rating for the company in a report on Wednesday, February 12th. Morgan Stanley upped their price target on shares of Edwards Lifesciences from $70.00 to $75.00 and gave the stock an “equal weight” rating in a research note on Wednesday, February 12th. Canaccord Genuity Group boosted their target price on Edwards Lifesciences from $68.00 to $71.00 and gave the stock a “hold” rating in a report on Thursday, February 13th. Barclays upped their target price on Edwards Lifesciences from $88.00 to $90.00 and gave the stock an “overweight” rating in a research report on Thursday, February 13th. Finally, Royal Bank of Canada reiterated an “outperform” rating and set a $85.00 price target on shares of Edwards Lifesciences in a research report on Wednesday, February 12th. One analyst has rated the stock with a sell rating, fourteen have assigned a hold rating and twelve have assigned a buy rating to the company. Based on data from MarketBeat, the stock has an average rating of “Hold” and a consensus price target of $79.95.

Insider Buying and Selling

In other Edwards Lifesciences news, VP Daniel J. Lippis sold 400 shares of Edwards Lifesciences stock in a transaction that occurred on Monday, March 10th. The shares were sold at an average price of $69.48, for a total value of $27,792.00. Following the completion of the sale, the vice president now directly owns 22,588 shares in the company, valued at $1,569,414.24. The trade was a 1.74 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO Bernard J. Zovighian sold 6,164 shares of the stock in a transaction on Monday, March 10th. The stock was sold at an average price of $69.51, for a total transaction of $428,459.64. Following the transaction, the chief executive officer now owns 59,083 shares in the company, valued at approximately $4,106,859.33. This trade represents a 9.45 % decrease in their position. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 51,303 shares of company stock worth $3,715,776. Corporate insiders own 1.29% of the company’s stock.

About Edwards Lifesciences

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.